New York, Jan 20, 2026, 18:10 EST — After-hours
Johnson & Johnson shares slipped 0.2% to $218.21 in after-hours trading on Tuesday, the session after the 4 p.m. close, as investors positioned for the drugmaker’s quarterly results due on Wednesday. The stock traded between $214.70 and $218.70 during the day.
The modest move came on a rough day for risk assets. The Dow fell 1.76%, the S&P 500 lost 2.06% and the Nasdaq dropped 2.39% as U.S. President Donald Trump’s tariff threats over Greenland hit sentiment, while the VIX — an options-based gauge of expected market swings — rose to an eight-week high of 20.99. “The geopolitical risks … are shifting market perceptions of common alliances across allies in Europe,” said Wasif Latif, chief investment officer at Sarmaya Partners. (Reuters)
For Johnson & Johnson, the timing matters. Earnings are landing early in the season, and traders are trying to decide what “defensive” really buys them when policy risk is driving the tape.
Analysts expect fourth-quarter profit of about $2.47 per share on revenue of $24.16 billion, and are looking for roughly a 21% jump in earnings from a year earlier, according to a Seeking Alpha earnings preview. The company is due to report before the opening bell. (Seeking Alpha)
Investors will dig for something simple: a clean 2026 outlook. That means guidance, any sign of price pressure, and whether medical devices can keep pace as hospitals keep a close eye on budgets.
Trade policy is now part of the checklist. The Trump administration is weighing a 100% tariff on imported brand-name and patented medicines, and drugmakers have been stockpiling inventory and pulling forward U.S. manufacturing plans to soften the blow, Reuters reported on Tuesday. Johnson & Johnson plans to lift U.S. investments by 25% to $55 billion over the next four years and build four plants, with rivals such as Pfizer, AstraZeneca and Merck also flagging big U.S. commitments. (Reuters)
Johnson & Johnson already has one deal on the books in Washington. Earlier this month it said it reached an agreement with the Trump administration to cut drug prices in exchange for tariff exemptions. “The joint agreement … provides the company’s pharmaceutical products an exemption from tariffs,” the company said. It also said it would participate in TrumpRx.gov and build new manufacturing facilities in North Carolina and Pennsylvania. (Reuters)
But the stock is not just an earnings story. Litigation risk still lurks, and it has a habit of flaring up at the worst moment.
A Baltimore jury in December ordered Johnson & Johnson and subsidiaries to pay more than $1.5 billion to a woman who developed mesothelioma after decades of using talc-based baby powder, and the company said it would appeal. Johnson & Johnson faces more than 67,000 lawsuits linking its talc products to cancer, Reuters reported. (Reuters)
If the company’s outlook disappoints, or if investors decide tariffs and price concessions will bite sooner than management expects, the stock can lose its “safe” label quickly. A steady forecast and a calm tone could do the opposite, especially if markets stay rattled.
Johnson & Johnson said it plans to post its fourth-quarter press release at about 6:45 a.m. ET on Wednesday and hold an investor call at 8:30 a.m. ET, hosted by Chief Executive Joaquin Duato, Chief Financial Officer Joseph J. Wolk and investor relations head Darren Snellgrove. (Jnj)
